Search results
Showing 31 to 45 of 62 results for rheumatology
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.
(APPG) for Axial Spondyloarthritis Versus Arthritis British Society for Rheumatology National Axial Spondyloarthritis Society Chartered...
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.
View recommendations for NG47Show all sections
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
of a toolkit (a 'how to guide') commissioned by the British Society of Rheumatology. For the in depth learning please refer to the BSR...
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
specialities in secondary care continue to be a challenge e.g. neurology, rheumatology and post-surgical use. The Medicines Management...
committee and a Commission on Human Medicine (CHM) Gastroenterology, Rheumatology, Immunology and Dermatology expert advisory group...
Discontinued [GID-TAG402]
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued [GID-TAG393]
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued [GID-TA10180]
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.